Recent

% | $
Quotes you view appear here for quick access.

BioTelemetry, Inc. Message Board

bluecheaps4mee 28 posts  |  Last Activity: 14 hours ago Member since: Feb 20, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Somebody likes this one !

  • Which reduces attacks by 50 pct. with up to 12 injections, RBC's Michael Yee says"

  • What does that mean ?

    It is so effective that no three stages required ?

    Plus the FDA giving fast track , so maybe Cowen & Co. is right.

  • I can only see the float, just under 29 Million shares.

  • Reply to

    80 pct did NOT complete trial?

    by tpstrong21 Jan 30, 2015 1:47 PM
    bluecheaps4mee bluecheaps4mee Jan 31, 2015 9:19 PM Flag

    Please folks don't be too hard on tpstrong21, in school, fourth grade was the best three years of his life, since then it's been tough sledding.

  • bluecheaps4mee bluecheaps4mee Jan 29, 2015 3:06 PM Flag

    You could be right, if they had a CC they would be in a situation that a question might come up that they would not want to discuss. Like a buy-out.

  • bluecheaps4mee bluecheaps4mee Jan 28, 2015 1:25 AM Flag

    Part #2

    "All FDA approved IV iron products for the treatment of iron deficiency anemia are iron-carbohydrate complexes, and it is the carbohydrate moiety that triggers the anaphylactoid or hypersensitivity reactions, Dr. Gupta said. SFP (= soluble ferric pyrophosphate = Triferic) does not contain carbohydrate, he said, pointing out that not a single anaphylactoid reaction has occurred in patients being given SFP, even after approximately 60,000 human doses administered in clinical trials. With IV iron products, these anaphylactoid reactions do occur, and in one called ferumoxytol (=Feraheme), patients have to remain under observation for at least 30 minutes after administration, leading to significant inconvenience and restrictions as to where the drug can be given."

  • Yesterday's news is the kill shot: Approval and imminent launch of Rockwell Medical's Triferic - a highly differentiated and disruptive new entry into the CKD market. Many analysts expect Triferic to quickly change the treatment paradigm of iron replacement therapy in dialysis patients. That's due to the unique method of administration of Triferic which is the only iron replacement therapy which can be delivered via the dialysate solution. This creates the potential for dialysis providers to realize significant savings in nursing time and syringes and supplies associated with the separate - and now no longer necessary - administration of IV iron. Health benefits also accompany the use of Triferic since it is slowly infused into the blood from the dialysate during dialysis in a manner which closely resembles the absorption of dietary iron. Data from two large Phase III clinical trials (Cruise-1 and Cruise-2, which enrolled a total of ~600 patients) demonstrated statistically significant achievement of the primary and key secondary endpoints (all relating to important hemoglobin levels) in both trials as well as an excellent safety profile which was comparable to placebo.

    A key motivator in the rapid adoption of Triferic will be its impact on reducing the usage of expensive erythropoiesis stimulating agents (ESAs, for example Amgen's EPO) by ~30-37% as demonstrated in a phase II trial. This translates in about $2,000 savings per patient per year. Although FDA did not allow an "ESA sparing claim" in the Triferic label (ODAC wanted a larger trial population), dialysis clinics are among the most economically savvy providers and will track the reduction in ESA usage and associated savings in real time and mandate Triferic uptake.

    Rockwell Medical may be a relatively small company, but it has a strong balance sheet and a laser-like focus on CKD with a ~$50 MM revenue business in dialysis solutions. More importantly, it has strong relationships with leading dialysis providers such as DaVita and also executed a distribution agreement with industry leader Baxter in October 2014. That relationship is currently limited to hemodialysis concentrates, but it would be entirely logical to amend it to also cover Triferic. In the meantime, Rockwell won't be shy about promoting Triferic's important features versus Feraheme as AJ Gupta, MD and Chief Scientific Officer of Rockwell recently highlighted in a medical journal:


    All FDA approved IV iron products

  • Reply to

    Adam is freaking out

    by toofadedtobeblue Jan 27, 2015 1:41 PM
    bluecheaps4mee bluecheaps4mee Jan 27, 2015 2:07 PM Flag

    I wonder how that BoZo lindabakker gets to post all her twitter links ? Look at her messages, she posts twitter links all over the place.

    How does yahoo pick and choose what links can be posted?

  • bluecheaps4mee bluecheaps4mee Jan 27, 2015 1:48 PM Flag

    Haha...I'm a moron ?

    Did they tell you that on..........TWITTER.......goofball ?

    LOL!

  • bluecheaps4mee bluecheaps4mee Jan 27, 2015 11:09 AM Flag

    Hey lindabakker, you sound like a real pro...............but you gotta go someplace else for your stock tips other than........TWITTER !

    Takes all kinds I guess.

  • All the names in the heading were associated in the past, and some still are in the present.

    Everybody knows about Ivan Boesky and Michael Milken, or at least SHOULD know of them.

    With very minimal research you can see what these #$%$ are, INCLUDING Jim Cramer, and his buddy Jonathon Aschoff (Brean Capital).

    It helps to be aware of the wolves in sheepskin.

  • Reply to

    Who cares

    by boyyoulove Jan 27, 2015 12:43 AM
    bluecheaps4mee bluecheaps4mee Jan 27, 2015 12:56 AM Flag

    We can not assume that everybody is aware of his credibility issues.

    Something from his past.

    "In 2003 – back when journalists still occasionally investigated stories, rather than parroting whatever hedge funds and Wall Street analysts whispered in their ears – The Wall Street Journal won a Pulitzer Prize for a story that nailed Jonathan Aschoff for being a fraud.

    According to the Journal, Aschoff often impersonated doctors in order to acquire inside information on the status of drug trials underway at his target companies. A certain Dr. Cunningham, who worked at a cancer center in Dallas, told the Journal that he initially believed that Aschoff was a doctor. But he discovered that he was dealing with a fraud when he mentioned to Aschoff that an experimental treatment had caused some reduction of the “lymphadenopathy.”

    “What’s that?” asked Aschoff. He didn’t have a clue, even though “lymphadenopathy” is a common medical term. It means, “swollen lymph nodes.”

  • And also........Jim Cramer’s Guide to Market Manipulation.

    This was with a Youtube video, but now I see they pulled the video, but the articles are still there.

    This Brean Capital guy is part of this Jim Cramer fraud gang.

    How CNBC allows this guy to be on their show is beyond me, his fraud activities are a well known fact, so they are not oblivious to his antics.

  • Brean sees FDA rejecting Rockwell's Triferic

    Dec 17 2013

    Brean is out with a decisively negative note on Rockwell Medical (RMTI), calling Triferic "far from terrific."
    Analyst Jonathan Aschoff doesn't mince words in initiating the shares at Sell: "We believe the FDA will reject Triferic due to poor clinical trial design and questionable efficacy."
    "CRUISE had a questionable design that we view as unlikely to result in approval," Aschoff says, elaborating. "More than 80% of the patients in all CRUISE arms did not complete the 48-week treatment period, making the primary endpoint evaluation period highly variable."
    Price target is $4, representing downside of more than 70% from Monday's close.
    For more on the CRUISE trials, see here.
    RMTI -7% premarket

    Apparently the FDA forgot to get in touch with "Analyst" Jonathon Aschoff on his thinking, to see if he still feels as he did back in ..............December of 2013.

    He says "We believe", besides himself I wonder who the "We" is?

    "questionable efficacy" ?

    The FDA went ahead and approved Triferic ................with "questionable efficacy" ?

  • January 7, 2014

    Rockwell Medical Announces Triferic(TM) PRIME ESA Sparing Study Selected as Best Abstract at 34th Annual Dialysis Conference in Atlanta, GA, February 8-11, 2014

  • Reply to

    The Street

    by rocksteady1203 Jan 26, 2015 6:56 PM
    bluecheaps4mee bluecheaps4mee Jan 26, 2015 8:53 PM Flag

    The Street looks at the Street from their rear-view mirror.

    Back there someplace is not where RMTI is now.

    Like going through a toll booth, okay you've paid your dues now.........now go ahead, take off.

  • Reply to

    Many positives on the horizon....

    by renalman55 Jan 26, 2015 4:43 PM
    bluecheaps4mee bluecheaps4mee Jan 26, 2015 7:30 PM Flag

    shortsgondown "WHERE IS THE LOVE" ? If there was zero love for RMTI today, with over 9 MILLION shares traded we would have been down 8 dollars, not 8 cents.

    You have to remember that ONE MONTH ago RMTI was as low as $8.10, in pre-market today it was as high as $13.49. Swing/Daytraders could not care less about how great a company is, or it's prospects, they are from the video game generation, they want to make a hit.........NOW!

    And then simply move on, no attachment whatsoever. They got into RMTI a month ago pretty much expecting very good positive news near term, and all they wanted was that quick fix.

    The bigger picture, or brighter horizon is totally meaningless to them.

    With the volume traded today, believe me there are lovers of RMTI out there, and now a lot of them are here as of today, and the couldn't care less people moved on to whatever.

    Be glad those types for the most part have departed.

  • "The results from the clinical trials have shown Triferic to be an effective and highly-differentiated iron delivery therapy with a safety profile similar to placebo."

    Read it slow, and without moving your lips, as many times as necessary.

    They are comparing the "safety" of Triferic to placebo..............NOT the efficacy of Triferic to placebo.

    They left out a comma after the word therapy, and the bashers think they are comparing Triferic's efficacy also to placebo.

  • Reply to

    Rockwell Announces Brean WRONG !

    by bluecheaps4mee Jan 26, 2015 3:39 PM
    bluecheaps4mee bluecheaps4mee Jan 26, 2015 4:04 PM Flag

    We are thanking you turd, for the opportunity to buy more at this temporary discounted price.

    Keep up the bad work.............you're real good at it.

BEAT
8.93+0.08(+0.90%)Apr 1 4:00 PMEDT